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S66 Other Specific Nephropathiesadriamycin. Furthermore, the TRPC6 upregulation leaded to the ILK upregu-
lation, and subsequent change of Fn, MMP9 and ZO-1, in part.http://dx.doi.org/10.1016/j.hkjn.2015.09.0230229
Preliminary Report of Anti-phospholipase A2 Receptor Antibody in
Idiopathic Membranous Nephropathy (IMN) in Xinjiang
Suhua Li, Minawar Yunusi, Li Zhang, Jianliu Liu, Shasha Liu, Xiaohong Sang
The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Objective: The aim of the present study was to investigate the status of
anti-phospholipase A2 receptor (anti-PLA2R) antibody in idiopathic membra-
nous nephropathy (IMN) in Xinjiang.
Methods: Patients with proteinuria were screened anti-PLA2R antibody from
April 2014 to June 2015. A total 516 patientswere screened. Among them, 76 pa-
tients receivedrenal biopsy, thepathologicdiagnosiswere IMN (28/76),membra-
nous proliferative glomerulopathy (13/76), minimal change disease (19/76), IgA
nephropathy (12/76), focal segmental glomerulosclerosis (1/76), lupus (3/76).
Anti-PLA2R was measured by Euro-immune commercial kit in all 516 patients.
Results: Patients included 53 men, 23 women, Han (47/76), Uygur (23/76)
and others (6/76). Seventy-six patients revealed positive anti-PLA2R anti-
body among 516 patients. In 28 IMN patients, positive anti-PLA2R antibody
were found in 25 patients, negative in 1 patient, and not measured in 2 pa-
tients. The specificity was 89.28%.
Conclusion: The specificity of anti-PLA2R antibody in IMN in Xinjiang is in
accordance with that reported in previous studies.http://dx.doi.org/10.1016/j.hkjn.2015.09.0240231
Experimental Study of Hematoxylon in Treating Membranous
Nephropathy Rats
Chengshou Song
Hospital, Qiqihar, China
Objective: To observe the effect of hematoxylon (water extract) on mem-
branous nephropathy (MN) in rats and clarify its significance in the treatment
of membranous nephropathy.
Methods: Membranous nephropathy Wistar rats were induced by C-BSA and
divided into groups randomly as follows: model group (Group B), hematoxy-
lin group (Group C), Tripterygium wilfordii group (Group D), hormone group
(Group E), 10 in every group. The control group (Group A) was additional.
Treatment groups were respectively given hematoxylin (decoction extract
granule), Tripterygium wilfordii tablets and prednisolone, fill stomach for
4 weeks in a row. 24-hour urinary protein were detected before and after us-
ing drugs administration. The first 4 weeks after treatment, the rats were
sacrificed, dedicated renal tissue, renal tissue sections HE staining, observa-
tion of rats in each group of kidney pathological changes under light micro-
scope. And conduct rat interleukin-18 (IL-18) quantitative enzymes.
Results: Model group, serum lipids, a 24-hour urinary protein continues to
rise, plasma protein sustain reduction. Hematoxylon group, Tripterygium
wilfordii group, hormone group trends related indicators have improved.
Light microscopic observation showed the glomerulus were swelling remark-
ably, the quantity of cells in glomerrulus increased significantly, glomerular
basement membrane became thicker, mesangium mesangial cell prolifera-
tion; in the treatment groups glomerular basement membrane thickening
are not obvious and injury lessened. Detection of IL-18 expression in the
treatment group than in model group decreased.
Conclusion: Rats using hematoxylon with membranous nephropathy, the
blood and urine tests have improved trends, rats improved the clinical man-
ifestations, pathology prompted hematoxylin on membranous nephropathy
rats therapeutic effect. IL-18 prompting hematoxylon at inhibiting the im-
mune response play a role.http://dx.doi.org/10.1016/j.hkjn.2015.09.0250239
Peroxisome Proliferator-activated Receptor g Agonist Pioglitazone
Prevents NF-kB Activation in Cisplatin Nephrotoxicity Through
Reduction of p65 Acetylation via the AMPK-SIRT1/p300 Pathway
Junhua Li, Ying Zhang, Ying Yao, Gang Xu
Tongji Hospital, Huazhong University of Science and Technology, Wuhan,
China
NF-kB is a ubiquitously expressed transcription factor controlling the
expression of numerous genes involved in inflammation. The aim of the
present study was to evaluate whether the activation of PPAR-g
attenuates the cisplatin-induced nuclear factor kB (NF-kB) activation in
cisplatin nephrotoxicity. The results showed that PPAR-g agonist piogli-
tazone decreased the expression of NF-kB p65 transcription target genes
[e.g., the pro-inflammatory cytokines interleukin-6 (IL-6), interleukin-1b
(IL-1b), and tumor necrosis factor-a (TNF-a)] and inhibited cell apoptosis
and inflammatory cell infiltration in cisplatin nephrotoxicity. The sup-
pression of NF-kB activity following pioglitazone treatment inhibited the
cisplatin-induced IkB-a degradation, phosphorylation modification and
NF-kB p65 subunit translocation. Translocation of the NF-kB p65 subunit
depends on p65 acetylation, and this translocation is primarily regulated
through SIRT1 or p300. Notably, AMP kinase (AMPK) activation not only
decreased the phosphorylation, activation and p65 interaction of p300
but also increased SIRT1 expression, activation and p65 binding, thus
leading to a significant reduction in p65 acetylation. Interestingly, the
reduction in the expression of IL-6, TNF-a and IL-1b, the inhibition of cell
apoptosis and the inflammatory cell infiltration following pioglitazone
treatment in cisplatin nephrotoxicity were attenuated after treatment
with the PPAR-g antagonist GW9662. These results suggest that the PPAR-
g agonist pioglitazone prevents NF-kB activation in cisplatin nephrotox-
icity through a reduction in p65 acetylation via the AMPK-SIRT1/p300
pathway.http://dx.doi.org/10.1016/j.hkjn.2015.09.0260241
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Background: Mercury intoxication is known to cause nephrotic syndrome;
most were reported to be membranous nephropathy but minimal
change disease has also been reported to be another pathological
manifestation.
Case Summary: We report a case of a 31-year-old Indonesian lady who pre-
sented with bilateral lower limb swelling and frothy urine for 2 weeks. She
had no fever and systemic upset. There was no family history of kidney dis-
eases, and there was no exposure to any over-the-counter medications. Her
facial skin was noted to be light-coloured compared with the skin colour in
her neck and limbs. She had been applying a set of facial lightening cream
for 6 months which had been purchased online. Laboratory investigations
showed significant proteinuria of 8.97 g/d, serum albumin 20 g/L, creatinine
47 umol/L, total cholesterol 11.03 mmol/L and triglycerides 4.99 mmol/L.
Autoimmune markers were negative. Her blood mercury level was
56 nmol/L (reference level < 45 nmol/L) and urine mercury was
334 nmol/d (reference level < 35 nmol/d). Renal biopsy consisted of 29
glomeruli and showed minimal change disease. The mercury content of
the cosmetic lightening day cream was 0.325 parts per million (ppm) and
the night cream was 6411 ppm, while the FDA allowable mercury level for
cosmetic ingredients is < 1 ppm. Chelating therapy was not given in view
of slightly elevated serum mercury level. Prednisolone was not given as
the minimal change disease was thought to be secondary to mercury intox-
ication. Low dose lisinopril 2.5 mg daily and simvastatin 20 mg daily were
commenced. After discontinuing the use of the cosmetic cream for 3 weeks,
her serum mercury level reduced to 20 nmol/L and the proteinuria signifi-
cantly improved to 0.7 g/d. At week 6, the proteinuria subsided and serum
albumin was normalized.
